41P - Impact on prognosis of cellular CD 69 expression with CD 38 in Egyptian chronic lymphocytic leukemia

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Leukaemia
Translational Research
Presenter Mohamed Elbaiomy
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors M.A. Elbaiomy1, S. Aref2, M. El-Ghonemy2
  • 1Medical Oncology, Oncology Center, 35541 - Mansoura/EG
  • 2Clinical Hematology, Oncology Center, 35541 - Mansoura/EG

Abstract

Background

Clinical variability in chronic lymphocytic leukemia with progress from indolent, with no need of treatment, to aggressive, with short morbidity and survival, still remains unclear. Several biological parameters have been added to the staging system to stratify those patients.

Methods

Our study includes 153 B-CLL patients recruited to Mansoura Oncology Center, in addition to 40 healthy controls matched in age and sex. Cellular CD69 expression was done by multiparameter flowcytometry in addition to routine immunophenotyping pattern of CLL.

Results

Patients with high CD69 expression were significantly associated with young age, leukocytosis, advanced Ria stage (III & IV), high B2M serum level and high bcl2 expression, while patients with low CD69 expression were significantly correlated with low CD38 expression. Higher CD69 expression was associated with shorter PFS (median, 16 months vs. 30 months; P = 0.001) and shorter OS (median, 20 months vs. 34 months; P ≤0.001). Patients with high CD38 expression were significantly associated with old age, leukocytosis, advanced Ria stage (III & IV), high B2M serum level and high bcl2 expression. Higher CD38 expression was associated with shorter PFS (median, 22 months vs. 30 months; P = 0.006) and shorter OS (median, 28 months vs. 34 months; P = 0.007). Combined high expression of both markers showed poor PFS (median, 14 months vs. 30 months in combined low expression; P = 0.002) also, combined high expression of both markers showed poor OS (median, 19 months vs. 34 months in combined low expression; P = 0.005). There was no biological effect of chemotherapy on PFS, OS. Cox proportional hazard regression showed that high CD69 expression was an independent prognostic factor for poor PFS (P = 0.01) along with high CD38 expression (P = 0.05). Also, high CD69 expression was an independent prognostic factor for poor OS (P = 0.016) along with high CD38 expression (P = 0.057).

Conclusions

CD69 and CD38 over expression predict adverse outcome and both could be applied in the scoring system of CLL as simple and easily applicable to stratify early progressive patients and so enabling timely therapeutic decisions to improve outcome.

Clinical trial indentification

.

Legal entity responsible for the study

OCMU

Funding

OCMU

Disclosure

All authors have declared no conflicts of interest.